SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 785.17+0.7%Dec 23 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: A.J. Mullen who wrote (3344)8/1/2021 9:09:54 PM
From: CuttingEdge Bio  Read Replies (2) of 3559
 
This is only for post-exposure prophylaxis, or "who are at high risk of exposure to an infected individual in an institutional setting"
It specifically excludes pre-exposure prophylaxis which they were hoping for to fully address the needs of immunocompromised patients. This severely restricts their ability to do that and makes it hard for such patients to access the drug.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News